Enterin
Clinical-stage biopharmaceutical company developing orally administered aminosterol-derived therapeutics that target the enteric nervous system to restore gut–brain signaling. The company has advanced a lead, locally acting enteric neuron therapeutic through preclinical studies and Phase 2 clinical trials in Parkinson’s disease and is developing additional aminosterol derivatives for metabolic indications. Work includes preclinical mechanism-of-action studies, multicenter randomized clinical trials, peer-reviewed publications, and regulatory engagements.
Industries
Nr. of Employees
small (1-50)
Enterin
Philadelphia, Pennsylvania, United States, North America
Patents
Aminosterol compositions and methods of using the same for treating schizophrenia
US-11464789-B2
View DetailsMethods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US-11440936-B2
View DetailsMethods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
US-11083735-B2
View DetailsMethods of treating and preventing gastrointestinal motility disorders using aminosterols
US-10975116-B2
View DetailsMethods of treating Parkinson's disease using aminosterols and compositions comprising the same
US-10633413-B2
View Details
Aminosterol compositions and methods of using the same for treating schizophrenia
US-11464789-B2
View DetailsMethods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US-11440936-B2
View DetailsMethods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
US-11083735-B2
View DetailsMethods of treating and preventing gastrointestinal motility disorders using aminosterols
US-10975116-B2
View DetailsMethods of treating Parkinson's disease using aminosterols and compositions comprising the same
US-10633413-B2
View DetailsProducts
Oral aminosterol-derived enteric neuron therapeutic (lead clinical candidate)
Orally administered, positively charged aminosterol-derived small molecule designed to act locally on enteric neurons to displace membrane-bound intracellular misfolded protein aggregates, restore enteric neuronal firing, improve gut motility, and modulate gut–brain signaling.
Oral aminosterol-derived metabolic candidate (preclinical)
Aminosterol-derived compound series evaluated preclinically for central insulin-sensitizing activity that increases insulin sensitivity, reduces food intake and produces weight loss in animal models.
Oral aminosterol-derived enteric neuron therapeutic (lead clinical candidate)
Orally administered, positively charged aminosterol-derived small molecule designed to act locally on enteric neurons to displace membrane-bound intracellular misfolded protein aggregates, restore enteric neuronal firing, improve gut motility, and modulate gut–brain signaling.
Oral aminosterol-derived metabolic candidate (preclinical)
Aminosterol-derived compound series evaluated preclinically for central insulin-sensitizing activity that increases insulin sensitivity, reduces food intake and produces weight loss in animal models.
Expertise Areas
- Gut–brain axis therapeutics
- Clinical trial management (Phase 2 multicenter randomized trials)
- Neurodegenerative disease pharmacology (Parkinson’s disease focus)
- Translational biomarker research linking infection, immunity and neuronal protein aggregation
Key Technologies
- Aminosterol-derived small molecules
- Enteric nervous system targeting
- Intraneuronal protein aggregate displacement assays
- Animal models for neurodegeneration (mouse, C. elegans)
News & Updates
FDA accepted an investigator-sponsored IND to treat a patient with prodromal multisystem atrophy using the orally administered enteric-targeted therapeutic; treatment described as ongoing under IND 166532.
Announcement that a randomized, placebo-controlled Phase 2b trial in Parkinson’s disease met primary and secondary bowel endpoints with statistically significant improvements versus placebo (CSBM primary endpoint p=0.0001).
Peer-reviewed article reporting that an oral, enteric-targeted aminosterol derivative targets enteric neurons to treat constipation in Parkinson’s disease; published in Annals of Internal Medicine.
Publication describing alpha-synuclein’s role in immune responses and implications for infection-induced neuronal alpha-synuclein accumulation.
Completion of a 150-patient randomized, double-blind, placebo-controlled Phase 2b study in Parkinson’s disease showing statistically significant improvement in primary bowel endpoint and sustained improvement post-treatment.
FDA accepted an investigator-sponsored IND to treat a patient with prodromal multisystem atrophy using the orally administered enteric-targeted therapeutic; treatment described as ongoing under IND 166532.
Announcement that a randomized, placebo-controlled Phase 2b trial in Parkinson’s disease met primary and secondary bowel endpoints with statistically significant improvements versus placebo (CSBM primary endpoint p=0.0001).
Peer-reviewed article reporting that an oral, enteric-targeted aminosterol derivative targets enteric neurons to treat constipation in Parkinson’s disease; published in Annals of Internal Medicine.
Publication describing alpha-synuclein’s role in immune responses and implications for infection-induced neuronal alpha-synuclein accumulation.
Completion of a 150-patient randomized, double-blind, placebo-controlled Phase 2b study in Parkinson’s disease showing statistically significant improvement in primary bowel endpoint and sustained improvement post-treatment.